Abstracts tagged "autoimmune diseases and rheumatoid arthritis (RA)"

Abstract Number: 2535 • 2018 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
Yujeong Shim¹, Seieun Kim¹, Maria Velinova², Gerhard Arold³, Semi Kim⁴, Young Il Choi⁴ and Kyung Mi Park⁵, ¹Product Development, Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ²PRA Health Sciences, Zuidlaren, Netherlands, ³PRA Health Sciences, Berlin, Germany, ⁴Research Institute of Chong Kun Dang Pharmaceutical Corporation, Yongin, Korea, Republic of (South), ⁵Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: HDAC6 is a pleiotropic enzyme which removes of acetyl groups from non-histone proteins. HDAC6 inhibition represses inflammatory responses such as cytokines, chemokines and cell…
Abstract Number: 531 • 2018 ACR/ARHP Annual Meeting
Association of Rheumatoid Arthritis and Other Autoinmune Diseases
Eliana Rebeca Serrano¹, Julia Sosa², María Paula Kohan², María Julia Santa Cruz¹, María Alejandra Medina¹, Diana Silvia Klajn³, Silvia Beatriz Papasidero⁴, José Ángel Caracciolo¹, Mariana Benegas⁵, Etel Saturansky⁶, Rosana Quintana⁷, Bernardo Pons Estel⁷, Dora Pereira⁸, Analía Dellepiane⁹, Rodrigo García Salinas¹⁰, María de los Angeles Correa¹¹, Gustavo Citera¹², Mónica Sacnun¹³, Claudia Hartvig¹⁴, Julia Demarchi¹⁵, Guillermo Bartel¹⁵, Andrea Gómez¹⁵, Karin Kirmayr¹⁶, José Velasco Zamora¹⁷, Yamila Chichotky¹⁸, María Marta Zalazar¹⁹, Oscar Rillo³, Analía Bohr²⁰, Adriana Pérez Dávila²¹, Hugo Najera²², Anastasia Secco²², Rene Jearmany Chuquimia²², Alejandro Martinez Muñoz²³, Emilio Buschiazzo²⁴, Ricardo Vicente Juárez²⁵, Laura Raiti²⁶, Vanesa Cruzat²⁶, Andrea Smichowski²⁷, Gustavo Casado²⁷, David Marcos Zelaya²⁸, Damaris Álvarez²⁸, Eduardo Kerzberg²⁹, Javier Rosa³⁰, Victoria García³¹, Cinthya Retamozo³², Ana Carolina Costi³³, Claudia Pena³⁴ and Hernán Maldonado Ficco³⁵, ¹Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, CABA, Argentina, ³Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, CABA, Argentina, ⁴Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ⁵Rheumatology Section, Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina, ⁶Rheumatology Section, Sanatorio Dr. Julio Méndez, CABA, Argentina, ⁷Rheumatology Section, Sanatorio Parque S.A., Rosario, Argentina, ⁸Rheumatology Section, Hospital Dr. Ricardo Gutiérrez, Argentina, Buenos Aires, Argentina, ⁹Rheumatology Section, CEMEC, Casilda-Santa Fe, Argentina, ¹⁰Rheumatology Section, Hospital Italiano de La Plata, La Plata, Argentina, ¹¹Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹²Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ¹³Rheumatology Section, Hospital Provincial de Rosario, Rosario, Argentina, ¹⁴Rheumatology Section, Hospital Provincial de Rosario, Rosario-Santa Fe, Argentina, ¹⁵Rheumatology Section, Hospital Británico de Buenos Aires, CABA, Argentina, ¹⁶Rheumatology Section, Sanatorio San Carlos de Bariloche, Bariloche, Argentina, ¹⁷Rheumatology Section, Reumatologia al Sur, Berazategui- Buenos Aires, Argentina, ¹⁸Rheumatology Section, Reumatologia al sur, Berazategui- Buenos Aires, Argentina, ¹⁹Rheumatology Section, Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires, Argentina, ²⁰Rheumatology Section, Hospital de Rehabilitación Manuel Rocca, Buenos Aires, Argentina, ²¹Rheumatology Section, Hospital de Rehabilitación Manuel Rocca, CABA, Argentina, ²²Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ²³Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, San Miguel- Buenos Aires, Argentina, ²⁴Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ²⁵Rheumatology Section, Hospital Señor del Milagro de Salta, Salta, Argentina, ²⁶Rheumatology Section, Clínica Bessone, San Miguel- Buenos Aires, Argentina, ²⁷Rheumatology Section, Hospital Militar Central, CABA, Argentina, ²⁸Rheumatology Section, Hospital General de Agudos José María Ramos Mejía, CABA, Argentina, ²⁹Rheumatology Section, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina, ³⁰Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ³¹Rheumatology Section, Hospital Italiano de Buenos Aires, CABA, Argentina, ³²Rheumatology Section, Centro Especializado Diabetes y Reumatologia, Orán- Salta, Argentina, ³³Rheumatology Section, Hospital Interzonal General de Agudos Gral. José de San Martín, La Plata, Buenos Aires, Argentina, ³⁴Rheumatology Section, Hospital San Martín de La Plata, La Plata- Buenos Aires, Argentina, ³⁵Rheumatology Section, Hospital San Antonio de Padua, Río Cuarto- Córdoba, Argentina
Background/Purpose: The coexistence of different autoimmune diseases (AID) has been well established in the literature. In our knowledge, there is no study assessing specifically the…
Abstract Number: 1035 • 2017 ACR/ARHP Annual Meeting
Risk of Hospitalization Among RA Patients with Multiple Autoimmune Co-Morbidities Differs By DMARD Treatment
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with autoimmune (AI) disorders are at higher risk of developing another AI disorder; co-occurrence of some AI conditions is reported more frequently…
Abstract Number: 2139 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Debra Zack¹, Maria Jaraczewska Baumann², Mariusz Korkosz³, Gabriella Suljok⁴, Petr Sramek⁵, Bernadette Rojkovich⁶, Stafan Daniluk⁷, Janos Bartalos⁸ and Paul Foster¹, ¹Xencor, Inc., San Diego, CA, ²NZOZ Centrum Medyczne HCP, Poznan, Poland, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴Drug Research Center Ltd., Baltonfüred, Hungary, ⁵PRA CZ, Praha, Czech Republic, ⁶Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, ⁷NZOZ Center of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ⁸PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: XmAb®5871 is a humanized Fc engineered monoclonal antibody that binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to…
Abstract Number: 3029 • 2015 ACR/ARHP Annual Meeting
Increased Plasticity of Non-Classic Th1 Cells Towards the Th17 Phenotype
Antonia Klose¹, Fausto Pirronello¹, Hendrik Schulze-Koops¹, Jan Leipe² and Alla Skapenko¹, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²Division of Rheumatology, University of Munich, Munich, Germany
Background/Purpose: Mechanisms underlying the predominance of Th17 cells observed in RA are not fully understood. Th cell plasticity is a potential mechanism leading to enrichment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].